| Literature DB >> 35800263 |
Ning Wang1, Jiaojiao Xi1, Chaoting Lan2, Yuxin Wu2, Yun Zhu1, Xiaoyu Zuo1, Yan Zhang1.
Abstract
Background: Hirschsprung's disease (HSCR) is a rare congenital disease in which enteric nervous system (ENS) in the distal intestine is absent. HSCR is a disease involving genetic factors and environmental factors. Despite a series of genes have been revealed to contribute to HSCR, many HSCR associated genes were yet not identified. Previous studies had identified that a potential susceptibility gene of HSCR was an inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP). The study aimed to explore the association of genetic variants in IKBKAP and HSCR susceptibility in southern Chinese children.Entities:
Keywords: B-cells, kinase complex-associated protein (IKBKAP); Hirschsprung’s disease (HSCR); genetic susceptibility; single nucleotide polymorphism (SNP)
Year: 2022 PMID: 35800263 PMCID: PMC9253937 DOI: 10.21037/tp-21-550
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Sample characteristics of the study subjects
| HSCR subphenotype | Cases (n=1,470) | Controls (n=1,473) | P |
|---|---|---|---|
| Gender, n (%) | |||
| Female | 240 (16.33) | 458 (31.09) | <0.001 |
| Male | 1,230 (83.67) | 1,015 (68.91) | <0.001 |
| Age (months), mean ± SD | 8.37±20.5 | 18.61±19.75 | <0.001 |
| Clinical manifestation, n (%) | |||
| S-HSCR | 1,033 (70.27) | N/A | – |
| L-HSCR | 294 (20.00) | N/A | – |
| TCA | 82 (5.58) | N/A | – |
| TIA | 3 (0.20) | N/A | – |
| Unknown subtype | 58 (0.70) | N/A | – |
SD, standard deviation; S-HSCR, short-segment HSCR; L-HSCR, long-segment HSCR; HSCR, Hirschsprung’s disease; TCA, total colonic aganglionosis; TIA, total intestinal aganglionosis.
Associations between selected polymorphism and Hirschsprung’s disease risk in southern Chinese children
| Genotype | Cases | Controls | Crude OR (95% CI) | P | Adjusted OR adj (95% CI) | Padj |
|---|---|---|---|---|---|---|
| rs2230793 T>G | n=1,442 | n=1,455 | ||||
| TT, n (%) | 828 (57.42) | 836 (57.46) | 1.00 | 1.00 | ||
| TG, n (%) | 538 (37.31) | 546 (37.52) | 1.00 (0.85–1.16) | 0.95 | 0.96 (0.81–1.13) | 0.60 |
| GG, n (%) | 76 (5.27) | 73 (5.02) | 1.05 (0.75–1.47) | 0.76 | 1.10 (0.77–1.57) | 0.59 |
| Additive, G count/T count | 690/2,194 | 692/2,218 | 1.01 (0.89–1.41) | 0.89 | 1.00 (0.88–1.14) | 1.00 |
| Dominant, TG+GG/TT | 614/828 | 619/836 | 1.00 (0.87–1.16) | 0.98 | 0.98 (0.83–1.14) | 0.76 |
| Recessive, GG/TT+TG | 76/1,366 | 73/1,382 | 1.06 (0.76–1.47) | 0.75 | 1.14 (0.80–1.61) | 0.48 |
| rs2275630 A>G | n=1,454 | n=1,461 | ||||
| AA, n (%) | 1,195 (82.19) | 1,206 (82.55) | 1.00 | 1.00 | ||
| AG, n (%) | 246 (16.92) | 238 (16.29) | 1.05 (0.86–1.27) | 0.65 | 1.03 (0.84–1.27) | 0.76 |
| GG, n (%) | 13 (0.89) | 17 (1.16) | 0.77 (0.37–1.60) | 0.49 | 0.87 (0.40–1.87) | 0.72 |
| Additive, G count/A count | 272/2,636 | 272/2,650 | 1.01 (0.85–1.20) | 0.93 | 1.01 (0.84–1.22) | 0.90 |
| Dominant, AG+GG/AA | 259/1,195 | 255/1,206 | 1.03 (0.85–1.24) | 0.78 | 1.02 (0.84–1.25) | 0.82 |
| Recessive, GG/AA+AG | 13/1,441 | 17/1,444 | 0.77 (0.37–1.59) | 0.48 | 0.87 (0.40–1.88) | 0.72 |
Additive, dominant, and recessive indicate the association test following dominant, recessive, and additive models, respectively. The P value indicates the significance based on different genetic models. The calculation of the OR is also based on the risk allele of each SNP. CI, confidence interval; OR, odds ratio; Padj, adjusted for age and gender; SNP, single nucleotide polymorphism; G, guanine; T, thymine; A, adenine.
Meta-analysis results for SNPs reported in previous studies on Hirschsprung’s disease
| SNP | Gene | BP | Study | Minor allele | OR | P | Pmeta | Q (%) | Phet |
|---|---|---|---|---|---|---|---|---|---|
| rs2230793 |
| 108897203 | Our data | G | 1.03 (0.91–1.17) | 0.900 | 0.08 | 86.8 | 0.006 |
| 110699304 | Tang | G | 1.58 (1.20–2.09) | 0.024 | |||||
| rs2275630 |
| 108900127 | Our data | G | 1.04 (0.87–1.24) | 0.950 | 0.16 | 78.0 | 0.033 |
| 110702228 | Tang | G | 1.68 (1.12–2.51) | 0.021 |
SNP, single nucleotide polymorphism; BP, base-pair where the SNP is located; G, guanine; OR, odds ratio; Pmeta, P value for meta-analysis; Q, Q-test for heterogeneity; Phet, P value for heterogeneity.
The association results of two independent SNPs with different subclinical features classified by aganglionosis length, including short-length (S-HSCR), long-length (L-HSCR) and TCA
| CHR | SNP | BP | A1/A2 | Gene | Test | Patient, A1 count/A2 count | Control, A1 count/A2 count | OR | P | Padj |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 | rs2230793 | 108897203 | G/T |
| S-HSCR | 471/1,559 | 692/2,218 | 1.00 (0.87–1.15) | 0.63 | 0.98 |
| L-HSCR | 151/431 | 692/2,218 | 1.16 (0.94–1.42) | 0.26 | 0.18 | |||||
| TCA | 47/117 | 692/2,218 | 1.33 (0.93–1.90) | 0.15 | 0.12 | |||||
| 9 | rs2275630 | 108900127 | G/A |
| S-HSCR | 184/1,862 | 272/2,650 | 1.01 (0.83–1.24) | 0.71 | 0.91 |
| L-HSCR | 54/528 | 272/2,650 | 1.03 (0.76–1.40) | 0.98 | 0.84 | |||||
| TCA | 26/142 | 272/2,650 | 1.81 (1.17–2.80) | 0.01 | 7.30E–03 |
The P value indicates the significance based on different genetic models. The calculation of the OR is also based on the risk allele of each SNP. A1/A2 indicate the risk allele and protective allele to disease, respectively. CHR, chromosome; SNP, single nucleotide polymorphism; BP, base-pair where the SNP is located; G, guanine; T, thymine; A, adenine; OR, odds ratio; Padj, P value adjusted for age and gender; TCA, total colonic aganglionosis; S-HSCR, short-segment HSCR; L-HSCR, long-segment HSCR; HSCR, Hirschsprung’s disease.
Figure 1Analysis of enhancer markers of rs2275630 previously reported in human fetal intestine.
Changes of TF before and after mutation with rs2275630
| TF | Combined position | Predicted target sequence (direction) | Score | P | q |
|---|---|---|---|---|---|
| Pre-mutation prediction binding TF | |||||
| | −14 to +1 | TTTCTGTTAGCTTTAT (–) | 11.2143 | 0.0000409 | 0.0138 |
| | −7 to +8 | TAACAGAAAACTATCA (+) | 11.1316 | 0.0000361 | 0.0115 |
| | −4 to +8 | TGATAGTTTTCTG (–) | 12.8333 | 0.000021 | 0.00761 |
| | −13 to +2 | GAAAACTATCAAGGAA (+) | 12.6111 | 0.0000154 | 0.00509 |
| Post-mutation prediction combined with TF | |||||
| | −13 to +2 | GAGAACTATCAAGGAA (+) | 12.3556 | 0.0000195 | 0.0065 |
ZNF92, zinc finger protein 92; SRF, serum response factor; MEIS1, myeloid ecotropic viral insertion site 1; BCL6, B-cell lymphoma 6; q, false discovery rate; TF, transcription factor.